Institute of Nano and Biopolymeric Materials, School of Materials Science and Engineering, Tongji University, 201804, Shanghai, China.
School of Polymer Science and Engineering, University of Southern Mississippi, Hattiesburg, MS, 39406, USA.
Signal Transduct Target Ther. 2022 Nov 19;7(1):379. doi: 10.1038/s41392-022-01243-0.
Cancer is a major threat to human health. Among various treatment methods, precision therapy has received significant attention since the inception, due to its ability to efficiently inhibit tumor growth, while curtailing common shortcomings from conventional cancer treatment, leading towards enhanced survival rates. Particularly, organelle-targeted strategies enable precise accumulation of therapeutic agents in organelles, locally triggering organelle-mediated cell death signals which can greatly reduce the therapeutic threshold dosage and minimize side-effects. In this review, we comprehensively discuss history and recent advances in targeted therapies on organelles, specifically including nucleus, mitochondria, lysosomes and endoplasmic reticulum, while focusing on organelle structures, organelle-mediated cell death signal pathways, and design guidelines of organelle-targeted nanomedicines based on intervention mechanisms. Furthermore, a perspective on future research and clinical opportunities and potential challenges in precision oncology is presented. Through demonstrating recent developments in organelle-targeted therapies, we believe this article can further stimulate broader interests in multidisciplinary research and technology development for enabling advanced organelle-targeted nanomedicines and their corresponding clinic translations.
癌症是严重威胁人类健康的一类疾病。在众多治疗方法中,精准治疗自诞生以来就备受关注,因为它能够高效抑制肿瘤生长,同时减少传统癌症治疗的常见缺点,提高生存率。特别是细胞器靶向策略可以使治疗剂在细胞器中精确积累,局部触发细胞器介导的细胞死亡信号,从而大大降低治疗阈值剂量并最小化副作用。在这篇综述中,我们全面讨论了细胞器靶向治疗的历史和最新进展,特别是细胞核、线粒体、溶酶体和内质网,同时重点介绍了细胞器结构、细胞器介导的细胞死亡信号通路以及基于干预机制的细胞器靶向纳米药物的设计原则。此外,还对精准肿瘤学未来的研究和临床机遇以及潜在挑战提出了展望。通过展示细胞器靶向治疗的最新进展,我们相信本文能够进一步激发人们对多学科研究和技术发展的广泛兴趣,以实现先进的细胞器靶向纳米药物及其相应的临床转化。
Signal Transduct Target Ther. 2022-11-19
Chem Commun (Camb). 2024-10-10
Asian J Pharm Sci. 2024-4
ACS Appl Mater Interfaces. 2021-5-5
Endocr Metab Immune Disord Drug Targets. 2024
Drug Resist Updat. 2017-5-21
Biomaterials. 2016-4-26
Signal Transduct Target Ther. 2023-8-7
Mol Biol Rep. 2025-9-10
Int J Nanomedicine. 2025-8-5
Clin Pharmacol. 2025-6-10
JACS Au. 2025-3-26
Bioact Mater. 2025-3-13
Front Pharmacol. 2025-2-27
Nanoscale Adv. 2020-8-19
Nanoscale Adv. 2020-6-19
Phys Rep. 2021-7-25
Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2022-9
Nat Rev Mol Cell Biol. 2022-5
ACS Appl Bio Mater. 2019-9-16
Mol Cell Biochem. 2022-2